CN107850600A - 用于前列腺疾病的生物标记物组合 - Google Patents

用于前列腺疾病的生物标记物组合 Download PDF

Info

Publication number
CN107850600A
CN107850600A CN201680042798.3A CN201680042798A CN107850600A CN 107850600 A CN107850600 A CN 107850600A CN 201680042798 A CN201680042798 A CN 201680042798A CN 107850600 A CN107850600 A CN 107850600A
Authority
CN
China
Prior art keywords
gpc
analyte
hgf
bph
cap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680042798.3A
Other languages
English (en)
Chinese (zh)
Inventor
B·沃尔什
D·坎贝尔
J·苏恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minomic International Ltd
Original Assignee
Minomic International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015902919A external-priority patent/AU2015902919A0/en
Application filed by Minomic International Ltd filed Critical Minomic International Ltd
Publication of CN107850600A publication Critical patent/CN107850600A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680042798.3A 2015-07-22 2016-07-22 用于前列腺疾病的生物标记物组合 Pending CN107850600A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015902919 2015-07-22
AU2015902919A AU2015902919A0 (en) 2015-07-22 Biomarker combinations for prostate disease
PCT/AU2016/000260 WO2017011855A1 (en) 2015-07-22 2016-07-22 Biomarker combinations for prostate disease

Publications (1)

Publication Number Publication Date
CN107850600A true CN107850600A (zh) 2018-03-27

Family

ID=57833476

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680042798.3A Pending CN107850600A (zh) 2015-07-22 2016-07-22 用于前列腺疾病的生物标记物组合

Country Status (8)

Country Link
US (1) US20180224454A1 (enExample)
EP (1) EP3325972B1 (enExample)
JP (1) JP6760666B2 (enExample)
KR (1) KR20180030549A (enExample)
CN (1) CN107850600A (enExample)
AU (1) AU2016297676B2 (enExample)
CA (1) CA2993102A1 (enExample)
WO (1) WO2017011855A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112313497A (zh) * 2018-04-27 2021-02-02 纳诺斯迪科公司 使用微流式细胞术诊断疾病的方法
CN113439212A (zh) * 2018-10-05 2021-09-24 美侬米克国际有限公司 用于确定侵袭性前列腺癌的生物标志物组合

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079269A3 (en) * 2006-12-19 2008-12-04 Yuri Nikolsky Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020784A2 (en) * 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
MX2009008096A (es) * 2007-02-02 2009-08-07 Novartis Ag Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos.
CA2936805C (en) * 2014-01-17 2024-02-20 Minomic International Ltd. Cell surface prostate cancer antigen for diagnosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079269A3 (en) * 2006-12-19 2008-12-04 Yuri Nikolsky Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MARGARET SULLIVAN PEPE, ET AL.: "Selecting Differentially Expressed Genes from Microarray Experiments.", 《BIOMETRICS》 *
NAUGHTON M, ET AL.: "Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer.", 《THE JOURNAL OF UROLOGY》 *
NEAL SHORE, ET AL.: "Glypican-1 as a biomarker for prostate cancer.", 《THE JOURNAL OF UROLOGY》 *
SHAILENDRA DWIVEDI, ET AL.: "Diagnostic and Prognostic Significance of Prostate Specific Antigen and Serum Interleukin 18 and 10 in Patients with Locally Advanced Prostate Cancer: A Prospective Study.", 《ASIAN PACIFIC J CANCER PREV》 *
XAVIER ROBIN, ET AL.: "pROC: an open-source package for R and S+ to analyze and compare ROC curves.", 《BMC BIOINFORMATICS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112313497A (zh) * 2018-04-27 2021-02-02 纳诺斯迪科公司 使用微流式细胞术诊断疾病的方法
CN113439212A (zh) * 2018-10-05 2021-09-24 美侬米克国际有限公司 用于确定侵袭性前列腺癌的生物标志物组合

Also Published As

Publication number Publication date
EP3325972B1 (en) 2020-08-19
AU2016297676A1 (en) 2018-02-01
US20180224454A1 (en) 2018-08-09
EP3325972A1 (en) 2018-05-30
JP6760666B2 (ja) 2020-09-23
HK1250257A1 (en) 2018-12-07
KR20180030549A (ko) 2018-03-23
JP2018520366A (ja) 2018-07-26
EP3325972A4 (en) 2019-02-27
AU2016297676B2 (en) 2022-09-01
WO2017011855A1 (en) 2017-01-26
CA2993102A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
CN113439212B (zh) 用于确定侵袭性前列腺癌的生物标志物组合
KR102208140B1 (ko) 전립선암의 바이오마커 검출에서 사용하기 위한 방법 및 어레이
CN109975549B (zh) 肿瘤来源IgG在胰腺癌诊断或预后中的用途
EP3325972B1 (en) Biomarker combinations for prostate disease
CN113302495B (zh) 膀胱癌的检测
EP3129785B1 (en) Diagnosis of cancer by detecting dimeric il-18
US20230305009A1 (en) Biomarker combinations for determining aggressive prostate cancer
CN113167798A (zh) 用于包含乐伐替尼和依维莫司的组合疗法的生物标志物
HK1250257B (en) Biomarker combinations for prostate disease
US20200271652A1 (en) Methods of Prognosing Early Stage Breast Lesions
US20240345092A1 (en) Risk prediction model for prostate cancer
Schneiderhan-Marra et al. Multiplexed immunoassays for the analysis of breast cancer biopsies
WO2024082026A1 (en) Methods for detecting aggressive prostate cancer
WO2025041833A1 (ja) がんの検査支援方法、及び検査キット

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180327

WD01 Invention patent application deemed withdrawn after publication